These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 15150186

  • 21. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.
    Vetter N, Cambronero-Hernandez E, Rohlf J, Simon S, Carides A, Oliveria T, Isaacs R, Protocol 020 Study Group.
    Clin Ther; 2002 Nov; 24(11):1770-85. PubMed ID: 12501873
    [Abstract] [Full Text] [Related]

  • 22. Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
    Tice AD, Turpin RS, Hoey CT, Lipsky BA, Wu J, Abramson MA.
    Am J Health Syst Pharm; 2007 May 15; 64(10):1080-6. PubMed ID: 17494908
    [Abstract] [Full Text] [Related]

  • 23. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
    Goldstein EJ, Snydman DR.
    J Antimicrob Chemother; 2004 Jun 15; 53 Suppl 2():ii29-36. PubMed ID: 15150181
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam.
    Zakrison TL, Hille DA, Namias N.
    Surg Infect (Larchmt); 2012 Feb 15; 13(1):38-42. PubMed ID: 22217196
    [Abstract] [Full Text] [Related]

  • 29. Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
    Jansen JP, Kumar R, Carmeli Y.
    Pharmacoeconomics; 2009 Feb 15; 27(12):1045-56. PubMed ID: 19908928
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections.
    Gesser RM, McCarroll KA, Woods GL.
    J Infect; 2004 Jan 15; 48(1):32-8. PubMed ID: 14667790
    [Abstract] [Full Text] [Related]

  • 32. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
    Hammond ML.
    J Antimicrob Chemother; 2004 Jun 15; 53 Suppl 2():ii7-9. PubMed ID: 15150178
    [Abstract] [Full Text] [Related]

  • 33. Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam.
    Teppler H, Meibohm AR, Woods GL.
    J Chemother; 2004 Feb 15; 16(1):62-9. PubMed ID: 15078001
    [Abstract] [Full Text] [Related]

  • 34. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults.
    Yellin AE, Hassett JM, Fernandez A, Geib J, Adeyi B, Woods GL, Teppler H, 004 Intra-abdominal Infection Study Group.
    Int J Antimicrob Agents; 2002 Sep 15; 20(3):165-73. PubMed ID: 12385694
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Ertapenem therapy for community-acquired pneumonia in the elderly.
    Woods GL, Isaacs RD, McCarroll KA, Friedland IR.
    J Am Geriatr Soc; 2003 Nov 15; 51(11):1526-32. PubMed ID: 14687380
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.
    Nix DE, Majumdar AK, DiNubile MJ.
    J Antimicrob Chemother; 2004 Jun 15; 53 Suppl 2():ii23-8. PubMed ID: 15150180
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Susceptibility to antibiotics of aerobic bacteria isolated from community acquired secondary peritonitis in children: therapeutic guidelines might not always fit with and everyday experience.
    Castagnola E, Bandettini R, Ginocchio F, Perotti M, Masa DL, Ciucci A, Loy A, Caviglia I, Haupt R, Guida E, Pini Prato A, Mattioli G, Buffa P.
    J Chemother; 2013 Aug 15; 25(4):213-6. PubMed ID: 23906074
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.